MYC deregulation sensitizes cancer cells to N-myristoyltransferase inhibition

Summary: Human N-myristoyltransferases (NMTs) catalyze N-terminal protein N-myristoylation and are promising targets in cancer, with an emerging mechanistic rationale for targeted therapy. Here, we screened 245 cancer cell lines against IMP-1320, a potent NMT inhibitor (NMTi), and conducted pathway-...

Full description

Saved in:
Bibliographic Details
Main Authors: Gregor A. Lueg, James Zhang, Monica Faronato, Andrii Gorelik, Wouter W. Kallemeijn, Francesco Falciani, Josephine Walton, Jack W. Houghton, Silvia Vannini, Evon Poon, Barbara M. Costa, Roberto Solari, Robin Carr, Andrew S. Bell, Edward J. Bartlett, Bernadette Brzezicha, Martin Janz, Louis Chesler, Dinis P. Calado, Edward W. Tate
Format: Article
Language:English
Published: Elsevier 2025-09-01
Series:Cell Reports
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2211124725009519
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849227045539676160
author Gregor A. Lueg
James Zhang
Monica Faronato
Andrii Gorelik
Wouter W. Kallemeijn
Francesco Falciani
Josephine Walton
Jack W. Houghton
Silvia Vannini
Evon Poon
Barbara M. Costa
Roberto Solari
Robin Carr
Andrew S. Bell
Edward J. Bartlett
Bernadette Brzezicha
Martin Janz
Louis Chesler
Dinis P. Calado
Edward W. Tate
author_facet Gregor A. Lueg
James Zhang
Monica Faronato
Andrii Gorelik
Wouter W. Kallemeijn
Francesco Falciani
Josephine Walton
Jack W. Houghton
Silvia Vannini
Evon Poon
Barbara M. Costa
Roberto Solari
Robin Carr
Andrew S. Bell
Edward J. Bartlett
Bernadette Brzezicha
Martin Janz
Louis Chesler
Dinis P. Calado
Edward W. Tate
author_sort Gregor A. Lueg
collection DOAJ
description Summary: Human N-myristoyltransferases (NMTs) catalyze N-terminal protein N-myristoylation and are promising targets in cancer, with an emerging mechanistic rationale for targeted therapy. Here, we screened 245 cancer cell lines against IMP-1320, a potent NMT inhibitor (NMTi), and conducted pathway-level analyses to identify that deregulated MYC increases cancer cell sensitivity to NMTis. Proteomics on detergent-enriched membrane fractions in MYC or MYCN-deregulated cancer cell models revealed that cell death is associated at least in part with loss of membrane association of mitochondrial respiratory complex I. This is concurrent with loss of myristoylation and degradation of the complex I assembly factor NDUFAF4, and induction of mitochondrial dysfunction, driven by MYC or MYCN-deregulation. NMTis eliminated or suppressed MYC- and MYCN-driven tumors in vivo without overt toxicity, suggesting that this constitutive co-translational protein modification can be targeted in MYC-driven cancers.
format Article
id doaj-art-ecd08d7f5cdd4c28a20917c61c386063
institution Kabale University
issn 2211-1247
language English
publishDate 2025-09-01
publisher Elsevier
record_format Article
series Cell Reports
spelling doaj-art-ecd08d7f5cdd4c28a20917c61c3860632025-08-24T05:12:07ZengElsevierCell Reports2211-12472025-09-0144911618010.1016/j.celrep.2025.116180MYC deregulation sensitizes cancer cells to N-myristoyltransferase inhibitionGregor A. Lueg0James Zhang1Monica Faronato2Andrii Gorelik3Wouter W. Kallemeijn4Francesco Falciani5Josephine Walton6Jack W. Houghton7Silvia Vannini8Evon Poon9Barbara M. Costa10Roberto Solari11Robin Carr12Andrew S. Bell13Edward J. Bartlett14Bernadette Brzezicha15Martin Janz16Louis Chesler17Dinis P. Calado18Edward W. Tate19Department of Chemistry, Molecular Sciences Research Hub, White City Campus, Imperial College London, 82 Wood Lane, W12 0BZ London, UK; The Francis Crick Institute, 1 Midland Road, NW1 1AT London, UKDepartment of Chemistry, Molecular Sciences Research Hub, White City Campus, Imperial College London, 82 Wood Lane, W12 0BZ London, UK; The Francis Crick Institute, 1 Midland Road, NW1 1AT London, UK; Division of Clinical Studies, The Institute of Cancer Research (ICR) & Royal Marsden NHS Trust, SW3 6JB London, UKDepartment of Chemistry, Molecular Sciences Research Hub, White City Campus, Imperial College London, 82 Wood Lane, W12 0BZ London, UK; The Francis Crick Institute, 1 Midland Road, NW1 1AT London, UKDepartment of Chemistry, Molecular Sciences Research Hub, White City Campus, Imperial College London, 82 Wood Lane, W12 0BZ London, UK; The Francis Crick Institute, 1 Midland Road, NW1 1AT London, UKDepartment of Chemistry, Molecular Sciences Research Hub, White City Campus, Imperial College London, 82 Wood Lane, W12 0BZ London, UK; The Francis Crick Institute, 1 Midland Road, NW1 1AT London, UKMyricx Pharma Limited, London Innovation Centre, 20 Water Street, E14 5GX London, UKDepartment of Chemistry, Molecular Sciences Research Hub, White City Campus, Imperial College London, 82 Wood Lane, W12 0BZ London, UK; Myricx Pharma Limited, London Innovation Centre, 20 Water Street, E14 5GX London, UKDepartment of Chemistry, Molecular Sciences Research Hub, White City Campus, Imperial College London, 82 Wood Lane, W12 0BZ London, UKDepartment of Chemistry, Molecular Sciences Research Hub, White City Campus, Imperial College London, 82 Wood Lane, W12 0BZ London, UKDivision of Clinical Studies, The Institute of Cancer Research (ICR) & Royal Marsden NHS Trust, SW3 6JB London, UKDivision of Clinical Studies, The Institute of Cancer Research (ICR) & Royal Marsden NHS Trust, SW3 6JB London, UKMyricx Pharma Limited, London Innovation Centre, 20 Water Street, E14 5GX London, UKMyricx Pharma Limited, London Innovation Centre, 20 Water Street, E14 5GX London, UKDepartment of Chemistry, Molecular Sciences Research Hub, White City Campus, Imperial College London, 82 Wood Lane, W12 0BZ London, UK; Myricx Pharma Limited, London Innovation Centre, 20 Water Street, E14 5GX London, UKDepartment of Chemistry, Molecular Sciences Research Hub, White City Campus, Imperial College London, 82 Wood Lane, W12 0BZ London, UKExperimental Pharmacology & Oncology Berlin-Buch, Robert-Rössle-Str. 10, 13125 Berlin, GermanyExperimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité – Universitätsmedizin Berlin, 13125 Berlin, GermanyDivision of Clinical Studies, The Institute of Cancer Research (ICR) & Royal Marsden NHS Trust, SW3 6JB London, UKThe Francis Crick Institute, 1 Midland Road, NW1 1AT London, UK; Peter Gorer Department of Immunobiology, School of Immunology & Microbial Sciences, King’s College London, The Francis Crick, SE1 9RT London, UK; Corresponding authorDepartment of Chemistry, Molecular Sciences Research Hub, White City Campus, Imperial College London, 82 Wood Lane, W12 0BZ London, UK; The Francis Crick Institute, 1 Midland Road, NW1 1AT London, UK; Myricx Pharma Limited, London Innovation Centre, 20 Water Street, E14 5GX London, UK; Corresponding authorSummary: Human N-myristoyltransferases (NMTs) catalyze N-terminal protein N-myristoylation and are promising targets in cancer, with an emerging mechanistic rationale for targeted therapy. Here, we screened 245 cancer cell lines against IMP-1320, a potent NMT inhibitor (NMTi), and conducted pathway-level analyses to identify that deregulated MYC increases cancer cell sensitivity to NMTis. Proteomics on detergent-enriched membrane fractions in MYC or MYCN-deregulated cancer cell models revealed that cell death is associated at least in part with loss of membrane association of mitochondrial respiratory complex I. This is concurrent with loss of myristoylation and degradation of the complex I assembly factor NDUFAF4, and induction of mitochondrial dysfunction, driven by MYC or MYCN-deregulation. NMTis eliminated or suppressed MYC- and MYCN-driven tumors in vivo without overt toxicity, suggesting that this constitutive co-translational protein modification can be targeted in MYC-driven cancers.http://www.sciencedirect.com/science/article/pii/S2211124725009519CP: CancerCP: Molecular biology
spellingShingle Gregor A. Lueg
James Zhang
Monica Faronato
Andrii Gorelik
Wouter W. Kallemeijn
Francesco Falciani
Josephine Walton
Jack W. Houghton
Silvia Vannini
Evon Poon
Barbara M. Costa
Roberto Solari
Robin Carr
Andrew S. Bell
Edward J. Bartlett
Bernadette Brzezicha
Martin Janz
Louis Chesler
Dinis P. Calado
Edward W. Tate
MYC deregulation sensitizes cancer cells to N-myristoyltransferase inhibition
Cell Reports
CP: Cancer
CP: Molecular biology
title MYC deregulation sensitizes cancer cells to N-myristoyltransferase inhibition
title_full MYC deregulation sensitizes cancer cells to N-myristoyltransferase inhibition
title_fullStr MYC deregulation sensitizes cancer cells to N-myristoyltransferase inhibition
title_full_unstemmed MYC deregulation sensitizes cancer cells to N-myristoyltransferase inhibition
title_short MYC deregulation sensitizes cancer cells to N-myristoyltransferase inhibition
title_sort myc deregulation sensitizes cancer cells to n myristoyltransferase inhibition
topic CP: Cancer
CP: Molecular biology
url http://www.sciencedirect.com/science/article/pii/S2211124725009519
work_keys_str_mv AT gregoralueg mycderegulationsensitizescancercellstonmyristoyltransferaseinhibition
AT jameszhang mycderegulationsensitizescancercellstonmyristoyltransferaseinhibition
AT monicafaronato mycderegulationsensitizescancercellstonmyristoyltransferaseinhibition
AT andriigorelik mycderegulationsensitizescancercellstonmyristoyltransferaseinhibition
AT wouterwkallemeijn mycderegulationsensitizescancercellstonmyristoyltransferaseinhibition
AT francescofalciani mycderegulationsensitizescancercellstonmyristoyltransferaseinhibition
AT josephinewalton mycderegulationsensitizescancercellstonmyristoyltransferaseinhibition
AT jackwhoughton mycderegulationsensitizescancercellstonmyristoyltransferaseinhibition
AT silviavannini mycderegulationsensitizescancercellstonmyristoyltransferaseinhibition
AT evonpoon mycderegulationsensitizescancercellstonmyristoyltransferaseinhibition
AT barbaramcosta mycderegulationsensitizescancercellstonmyristoyltransferaseinhibition
AT robertosolari mycderegulationsensitizescancercellstonmyristoyltransferaseinhibition
AT robincarr mycderegulationsensitizescancercellstonmyristoyltransferaseinhibition
AT andrewsbell mycderegulationsensitizescancercellstonmyristoyltransferaseinhibition
AT edwardjbartlett mycderegulationsensitizescancercellstonmyristoyltransferaseinhibition
AT bernadettebrzezicha mycderegulationsensitizescancercellstonmyristoyltransferaseinhibition
AT martinjanz mycderegulationsensitizescancercellstonmyristoyltransferaseinhibition
AT louischesler mycderegulationsensitizescancercellstonmyristoyltransferaseinhibition
AT dinispcalado mycderegulationsensitizescancercellstonmyristoyltransferaseinhibition
AT edwardwtate mycderegulationsensitizescancercellstonmyristoyltransferaseinhibition